GI
SMMT icon

GAMMA Investing’s Summit Therapeutics SMMT Stock Holding History

GAMMA Investing’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.3K Buy
1,668
+29
+2% +$514 ﹤0.01% 2737
2026
Q1 		$31.1K Buy
1,639
+834
+104% +$13.5K ﹤0.01% 2484
2025
Q4 		$14.1K Sell
805
-173
-18% -$3.25K ﹤0.01% 2805
2025
Q3 		$20.2K Buy
978
+67
+7% +$1.63K ﹤0.01% 2508
2025
Q2 		$19.4K Buy
911
+86
+10% +$1.96K ﹤0.01% 2476
2025
Q1 		$15.9K Buy
825
+242
+42% +$4.86K ﹤0.01% 2516
2024
Q4 		$10.4K Buy
583
+106
+22% +$2.06K ﹤0.01% 2594
2024
Q3 		$10.4K Buy
477
+449
+1,604% +$6.28K ﹤0.01% 2438
2024
Q2 		$218 Sell
28
-2
-7% -$11 ﹤0.01% 3320
2024
Q1 		$124 Buy
+30
New +$119 ﹤0.01% 3276

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

GAMMA Investing's SMMT Position: Q2 2026 in Review

GAMMA Investing increased its Summit Therapeutics (SMMT) stake by 1.8% in Q2 2026, buying an estimated $514 and bringing the position to 1,668 shares worth $24.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2737.

GAMMA Investing first reported a position in SMMT in Q1 2024 and has held it in 10 quarters since. The position peaked at $31.1K in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • GAMMA Investing held 1,668 shares of Summit Therapeutics worth $24.3K as of Q2 2026.
  • GAMMA Investing bought 29 Summit Therapeutics shares in Q2 2026, an estimated $514.
  • Summit Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #2737 holding.
  • GAMMA Investing first reported a position in Summit Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • GAMMA Investing's Summit Therapeutics position peaked at $31.1K in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.